Ignite Creation Date:
2025-12-24 @ 4:05 PM
Ignite Modification Date:
2025-12-29 @ 9:59 PM
Study NCT ID:
NCT01568866
Status:
COMPLETED
Last Update Posted:
2022-11-14
First Post:
2012-03-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
Sponsor:
Amgen
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-06-20
Start Date Type:
ACTUAL
Primary Completion Date:
2014-11-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-02-05
Completion Date Type:
ACTUAL
First Submit Date:
2012-03-28
First Submit QC Date:
None
Study First Post Date:
2012-04-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2015-11-06
Results First Submit QC Date:
None
Results First Post Date:
2015-12-11
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-11-10
Last Update Post Date:
2022-11-14
Last Update Post Date Type:
ACTUAL